STOCK TITAN
  1. Home
  2. News
  3. ONTX

Onconova Therapeutics Inc - ONTX STOCK NEWS

Welcome to our dedicated news page for Onconova Therapeutics (Ticker: ONTX), a resource for investors and traders seeking the latest updates and insights on Onconova Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Onconova Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Onconova Therapeutics's position in the market.

News
Traws Pharma Announces New Employee Inducement Grants
Rhea-AI Summary
Traws Pharma, Inc. announced equity awards to new employees post the acquisition of Trawsfynydd Therapeutics, Inc. by Onconova Therapeutics, Inc. The awards include restricted stock equity grants to key individuals, with specific vesting conditions over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
management
-
News
Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company
Rhea-AI Summary
Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. have merged to form Traws Pharma, Inc., focusing on developing antivirals for influenza, COVID-19, and other infectious diseases. The merger will result in the new ticker symbol 'TRAW' on NASDAQ. The companies plan to raise $14 million through a private placement, expecting a cash balance of $28 million. Traws Pharma will advance the development of viroksavir, travaltrevir, and narazaciclib, with multiple catalysts expected in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
none
-
News
Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024
Rhea-AI Summary
Onconova Therapeutics, Inc. (NASDAQ: ONTX) announced the presentation of preclinical studies at AACR 2024, focusing on characterizing rigosertib's mechanisms impacting cancer pathways. The studies highlighted rigosertib's impact on RAS-MAPK signaling, ROS-related proteins, and inflammation-related targets, potentially aiding in developing treatment regimens for challenging cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.87%
Tags
none
News
Onconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma
Rhea-AI Summary
Onconova Therapeutics, Inc. (NASDAQ: ONTX) announced preclinical data demonstrating narazaciclib's potential to inhibit tumor growth in ibrutinib-sensitive and -resistant settings, along with its ability to promote G1 cell cycle blockade and metabolic reprogramming. The company is planning dose escalation studies in lead indication LGEEC with a planned update in H1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.13%
Tags
none
-
News
Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s
Rhea-AI Summary
Onconova Therapeutics, Inc. (NASDAQ: ONTX) announced preclinical data highlighting narazaciclib’s multi-kinase profile, broad anti-tumor activity, and increased anti-tumor immunity, compared to palbociclib and other CDK4/6 inhibitors. The data supports the potential use of narazaciclib in breast and ovarian cancers, with plans for registrational studies and update in H1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
Rhea-AI Summary
Onconova Therapeutics, Inc. (ONTX) to Present at Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.99%
Tags
conferences acquisition
News
Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results
Rhea-AI Summary
Onconova Therapeutics, Inc. (NASDAQ: ONTX) reports progress on the registrational preparations for the narazaciclib program, highlighting target engagement and an acceptable safety profile. The company also confirms plans for the rigosertib trial and financial results for the third quarter of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.55%
Tags
earnings
-
News
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023
Rhea-AI Summary
Onconova Therapeutics, Inc. (NASDAQ: ONTX) to host conference call and webcast on November 14, 2023 to discuss third quarter 2023 financial results and pipeline programs
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
earnings
-
News
Onconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCL
Rhea-AI Summary
Onconova Therapeutics announced that preclinical data shows narazaciclib's effectiveness in controlling tumor growth in mantle cell lymphoma, including resistant cases. The combination of narazaciclib and ibrutinib also demonstrated anti-tumor activity. The studies support the potential use of narazaciclib in MCL and other cyclin-dependent indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
none
News
Onconova Expands Leadership Team with Two Key Appointments
Rhea-AI Summary
Onconova Therapeutics has named Dr. Victor Moyo as Chief Medical Officer and Meena Arora as Vice President of Global Medical Affairs and R&D. Both appointments are expected to contribute to the success of the company's oncology programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
management
Stock ONTX logo
Onconova Therapeutics Inc

Nasdaq:ONTX

ONTX Rankings

N/A Ranked by Market Cap
#2950 Ranked by Stock Gains
N/A Ranked by Dividends

ONTX Stock Data

20.90M
20.84M
0.78%
7.95%
0.1%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Newtown

About ONTX

onconova therapeutics, inc. (nasdaq: ontx) is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. using a proprietary chemistry platform, onconova has created an extensive library of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. onconova has three product candidates in clinical trials and six active pre-clinical programs. onconova seeks to develop products that improve the outcome for cancer patients by directly addressing the disease, its recurrence, and the burden of side-effects associated with current methods of treatment.